Using Mirabegron to Increase BP in Patients With POTS

Summary

This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments. The American Heart Association funds this study.

Timeline

Start

2023-12-22

Primary completion

2025-05-20

Completion

2025-07-25

Drugs

Indications